

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Broncus Holding Corporation

壑博医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2216)

VOLUNTARY ANNOUNCEMENT

BRONCTRU® DISPOSABLE TRANSBRONCHIAL PUNCTURE DILATION CATHETER OBTAINED EU MDR CE MARKING

This announcement is made by Broncus Holding Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors of the latest updates on the business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that BroncTru® Disposable Transbronchial Puncture Dilation Catheter (“**BroncTru®**”), independently developed by the Company, has recently obtained European Union Medical Device Regulation (the “**EU MDR**”) CE marking, representing a significant advancement in the Company’s international registration and global product presence.

BroncTru® incorporates multiple patented technologies. Under the guidance of the navigation system, BroncTru® enables precise access to peripheral pulmonary nodules that are difficult to reach with conventional bronchoscopes. Through the steps of puncture, dilation and tunnel creation, it establishes a direct working channel for other endoscopic instruments to reach target lesions within the lungs, serving as a core tool for performing Bronchoscopic Transparenchymal Nodule Access (BTPNA). BroncTru® can be used in combination with diagnostic and therapeutic products to rapidly achieve diagnosis and treatment of lesions throughout the lungs. Its application scenarios include, but are not limited to, various existing bronchoscopic biopsy and sampling procedures, such as endobronchial ultrasound-guided transbronchial tunnel cryobiopsy (EBUS-TTCB), endobronchial ultrasound-guided sheath transbronchial lung biopsy (EBUS-GS-TBLB), transbronchial needle aspiration (TBNA), bronchoscopic lung cavity puncture biopsy and lavage, transbronchoscopic targeted drug delivery via the dilatation catheter, transbronchoscopic ablation procedures, and transbronchoscopic-assisted localization. These applications enable BroncTru® to comprehensively meet diverse clinical diagnostic and therapeutic needs.

The receipt of the EU MDR CE marking signifies BroncTru®'s compliance with the latest European Union Medical Device Regulation requirements, laying a solid foundation for the Company to further expand into Europe and other markets recognizing CE marking. EU CE marking is a mandatory qualification certificate for medical devices entering the European market, demonstrating that the product complies with the EU MDR. It also further enriches our international product portfolio and helps enhance the Company's global commercialization capabilities and competitiveness in international markets.

As of the date of this announcement, BroncTru® has obtained registration approvals from the National Medical Products Administration (NMPA) of China, the U.S. Food and Drug Administration (FDA) and the EU MDR CE, and has been approved for marketing in Taiwan, China, Indonesia, Thailand and Malaysia.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Broncus Holding Corporation
XU Hong
Chairman

Hong Kong, July 27, 2026

As at the date of this announcement, the Board comprises Mr. Hong Xu as executive Director, Mr. Ao Zhang and Ms. Yanhong Kuang as non-executive Directors, and Dr. Pok Man Kam, Ms. Yee Sin Wong and Dr. David Scott Lim as independent non-executive Directors.